- Trial phase
- Phase 1
- Time to market
- VAX-A1 is in Phase 1 testing with topline data expected in the second half of 2027. If Phase 1 is successful, the drug would need to complete Phase 2 and Phase 3 trials before any regulatory submission, placing a potential approval many years away (likely 2030 or later, assuming success at every stage).
- Why 4/10
- The next hard catalyst for VAX-A1 is the Phase 1 topline data readout expected in the second half of 2027 (approximately 8-13 months from today). However, VAX-A1 is an early-stage program at a company whose valuation is overwhelmingly driven by its lead pneumococcal conjugate vaccine franchise (VAX-31/VAX-24). A Phase 1 safety/immunogenicity readout on a non-lead asset does not constitute a binary event for the stock, capping the impact score at 4.
The next catalyst for VAX-A1 is the Phase 1 topline safety, tolerability and immunogenicity data readout expected in the second half of 2027. Positive data would validate Vaxcyte's platform in a new bacterial target (Group A Strep) and open a large unserved market, but Phase 1 readouts are early-stage and the stock's primary driver remains the VAX-31 pneumococcal franchise. The Q3 2026 earnings update noted the study advanced to Stage 2 after a positive DSMB review of Stage 1 safety data, a modest incremental positive.
Price Chart
Executive Summary
VAX-A1 is Vaxcyte's Phase 1 preventive vaccine candidate for Group A Streptococcus (Strep A), a bacterial infection that causes over 500,000 deaths annually and for which no approved vaccine currently exists. The first participant was dosed in a Phase 1 first-in-human study in June 2026, and the study has since advanced to Stage 2 after a positive DSMB safety review. Topline safety, tolerability and immunogenicity data are expected in the second half of 2027. VAX-A1 is an early-stage, non-lead program for Vaxcyte; the company's primary value driver is its pneumococcal conjugate vaccine franchise (VAX-31, which reported positive Phase 3 OPUS-1 data in October 2026, and VAX-24). Vaxcyte has a strong balance sheet (~$3.4B pro forma cash) and broad analyst support (mean price target $117.30, ~89% upside from ~$64).
How It Works
VAX-A1 is a preventive vaccine (given before infection) designed to train the immune system to recognize and fight Group A Streptococcus (Strep A) bacteria. It is a conjugate vaccine, meaning it links a sugar molecule from the bacterium's surface to several protein targets (C5a peptidase, streptolysin O, and SpyAD) to produce a stronger and broader immune response. The vaccine aims to provide protection across many different subtypes of Strep A, which is important because the bacteria has many strains.
Trial Status
VAX-A1 is in a Phase 1, first-in-human, randomized, double-blind, placebo-controlled, two-stage dose-escalation study in approximately 80 healthy adults aged 18-40 in Australia. The primary objective is safety and tolerability; secondary objectives include antigen-specific immune responses. The first participant was dosed in June 2026. As of the Q3 2026 earnings update (November 4, 2026), the study had advanced to Stage 2 following an independent Data Safety Monitoring Board (DSMB) review of Stage 1 safety data.
The Two-Sided Case
Upcoming Catalysts
- Phase 1 topline safety, tolerability and immunogenicity data readout expected in the second half of 2027
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Vaxcyte, Inc. 8-K PCVX ·Originating report